Show simple item record

dc.contributor.advisor曾锦章
dc.contributor.advisor吴云龙
dc.contributor.author王培钰
dc.date.accessioned2018-12-05T01:49:00Z
dc.date.available2018-12-05T01:49:00Z
dc.date.issued2018-04-09
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/170790
dc.description.abstract非酒精性脂肪肝是一直困扰我国和全世界人口的慢性疾病,发病率在20%左右,也就是说每5个中国人,就有一个是非酒精性脂肪肝的携带者。而FDA推荐的《非酒精性脂肪肝病诊疗指南》中,并没有明确有效的预防和治疗非酒精性脂肪肝的药物。所以,明确肝脏细胞脂质代谢的调控机制,筛选出可以改善脂质堆积的药物是迫在眉睫的。本课题通过80份病例的分析,试图寻找到能够调控脂质代谢中关键的转录因子SREBP-1c的蛋白。我们使用组织免疫的方法来检测患者肝脏穿刺样品中的Nur77表达量。结果发现,随着病情的加重Nur77表达量逐步降低,而SREBP-1c的含量则有显著地上调。随后,我们又建立了非酒精性脂肪肝的细胞体外和小鼠...
dc.description.abstractNonalcoholic fatty liver is a chronic disease that has plagued our country and the world's population. The incidence rate is about 20%, which means there is one non-alcoholic fatty liver carrier every five Chinese people. Even though in FDA recommended "non-alcoholic fatty liver disease diagnosis and treatment guidelines", there is no clear and effective prevention and treatment of non-alcoholic f...
dc.language.isozh_CN
dc.relation.urihttps://catalog.xmu.edu.cn/opac/openlink.php?strText=59904&doctype=ALL&strSearchType=callno
dc.source.urihttps://etd.xmu.edu.cn/detail.asp?serial=59684
dc.subjectNon-Alcoholic Fatty Liver Disease
dc.subjectNur77
dc.subjectSREBP
dc.subject非酒精性脂肪肝
dc.subject孤儿核受体Nur77
dc.subject胆固醇调节元件结合蛋白
dc.title核受体Nur77可以通过与SREBP-1c相互作用改善非酒精性脂肪肝中的脂质堆积
dc.title.alternativeThe nuclear receptor Nur77 could improve the lipid accumulation in Non-Alcoholic Fatty Liver Disease (NAFLD) in cooperation with SREBP-1c
dc.typethesis
dc.date.replied2017-05-17
dc.description.note学位:理学硕士
dc.description.note院系专业:药学院_化学生物学
dc.description.note学号:32320141153398


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record